title: Rivaroxaban for the treatment of saphenous vein graft thrombosis.
abstract: Thrombus formafigtion plays a significant role in disease of saphenous vein bypass grafts. Use of oral anticoagulants has not been tested in treatment of thrombotic occlusion of saphenous vein graft (SVG) disease. Here we describe the use of the novel oral anticoagulant rivaroxaban in the treatment of occlusive SVG disease with intraluminal thrombus, leading to successful recanalization.
authors.affiliation: Citizens Memorial Hospital, Heart and Vascular Institute, Bolivar, MO, USA.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Marmagkiolis
authors.affiliation: Arkansas Heart Hospital/University of Arkansas for Medical Sciences, Little Rock, AR, USA; Koc University, School of Medicine, Istanbul, Turkey. Electronic address: cilingiroglumehmet@gmail.com.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Cilingiroglu
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D005260:Female; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D000069552:Rivaroxaban / Q000627:therapeutic use*; D012501:Saphenous Vein / Q000000981:diagnostic imaging; D020246:Venous Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy*
chemical_list: D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban
keywords: Anticoagulant; Anticoagulantes; Doença do enxerto da veia safena; Saphenous vein graft disease; Thrombus; Trombose